Zogenix offers needle-free sumatriptan for headaches; Antibiotic Trojan horse for cholera may be possible;

> Migraines are awful, and sumatriptan, the first available of the triptans, revolutionized their treatment but had to be delivered as a shot, immediately cutting its market. Zogenix ($ZGNX) has presented a case study of its repositioning of injectable sumatriptan using its needle-free technology at the 2nd Annual Drug Repositioning & Indications Discovery Conference. This showed that the reformulation with the DosePro needle-free delivery system increased both physician and patient use of sumatriptan. Press release

> Research to work out how Vibrio cholerae, the bacterium behind cholera, originally became the deadly pathogen that it is now could lead to a better way of delivering antibiotics. Article

> Dr. Reddy's is bidding to buy Dutch company OctoPlus as a standalone unit to expand drug delivery; no job cuts are anticipated. Article

> Catalent Pharma Solutions has created a drug delivery institute through industry-academia partnerships that aims to improve drug delivery. Article

> Contraceptive transdermal patches or vaginal rings are associated with increased risk of venous thrombosis. Abstract

> Capsugel's thermogelled HPMC capsules, plant-based capsules made from hypromellose (HPMC) using a thermal gelling process instead of gelling agents, dissolve more predictably. Press release

And Finally… Mouse models can predict cancer drug delivery in humans. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.